Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8443767 | European Journal of Cancer | 2014 | 8 Pages |
Abstract
In this trial replacing the last 2 FEC100 cycles of 6FEC100 regimen by 4 Taxol does not lead to a discernable DFS or OS advantage. The lack of a significant difference between the randomised treatment arms may however be due to a lack of power of this trial to detect small, yet clinically worthwhile, treatment benefits.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
C. Delbaldo, D. Serin, M. Mousseau, S. Greget, B. Audhuy, F. Priou, J.F. Berdah, E. Teissier, P. Laplaige, L. Zelek, E. Quinaux, M. Buyse, P. Piedbois,